Kazano Tablet, Film Coated
Product Images NDC 64764-337

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Kazano (NDC 64764-337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Kazano 01)

Chemical structure of alogliptin, one of the active ingredients in KAZANO (alogliptin and metformin hydrochloride). The structure depicts molecular bonds and functional groups characteristic of alogliptin.*

FDA Label Image

Chemical Structure (Kazano 02)

Chemical structure diagram of alogliptin, an active ingredient in the drug KAZANO (alogliptin and metformin hydrochloride). The structure shows the molecular layout including nitrogen, carbon, and hydrogen atoms with a hydrochloride component indicated.*

FDA Label Image

Figure 1 (Kazano 03)

A comparative chart depicting the pharmacokinetic impact of alogliptin on various coadministered drugs, listed with dosing details under different enzymatic substrates (renal excreted, CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4, and Pgp). The chart includes ratios and 90% confidence intervals for AUC and Cmax, along with corresponding dosage adjustment recommendations, which uniformly indicate 'No dose adjustment.'*

FDA Label Image

Figure 2 (Kazano 04)

A forest plot chart comparing the pharmacokinetic ratio and 90% confidence interval of alogliptin when coadministered with various drugs. The X-axis shows the ratio of alogliptin plus the other drug versus alogliptin alone. Drugs listed include metformin, cimetidine, gemfibrozil, pioglitazone, fluconazole, ketoconazole, atorvastatin, cyclosporine, and digoxin. Recommendations for dose adjustment are stated as 'No dose adjustment' for all drugs.*

FDA Label Image

Figure 3 (Kazano 05)

A bar chart depicting least squares mean change in A1C (%) for different treatments: Placebo, Alogliptin, Metformin, and combinations of Alogliptin with Metformin. The chart shows baseline values around 8.4 to 8.5 and mean reductions indicating greater A1C lowering with combination therapies compared to individual treatments and placebo. Statistical significance is noted for combination treatments compared to monotherapies.*

FDA Label Image

Figure 4 (Kazano 06)

A Kaplan-Meier cumulative event probability curve comparing alogliptin and placebo over 30 months from randomization. The graph shows cumulative event probabilities on the vertical axis and months on the horizontal axis. It includes numbers at risk over time for both groups and a hazard ratio with a 95% confidence interval for alogliptin versus placebo.*

FDA Label Image

Principal Display Panel (12.5 MG/500 MG)

Label for Kazano tablets containing alogliptin and metformin hydrochloride with strength 12.5 mg/500 mg. The label shows the product name, active ingredients, dosage form as film-coated tablets, and package count of 60 tablets. It is distributed by Takeda Pharmaceuticals America, Inc. Warnings and storage instructions are included along with the NDC 64764-335-60 and a barcode.*

FDA Label Image

Principal Display Panel (12.5 MG/1000 MG)

Label for Kazano tablets with alogliptin and metformin hydrochloride, 12.5 mg/1000 mg strength. The film-coated oral tablets are distributed by Takeda Pharmaceuticals America, Inc. The label includes dosage details, storage instructions, quantity of 60 tablets, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.